

## Figure index

Figure 1. 1 Classification of depressive disorders .....	1
Figure 1. 2 Symptoms of depression .....	2
Figure 1. 3 Endosomal escape mechanism for liposomes containing cDNA .....	19
Figure 1. 4 Various shape of liposomal structure .....	22
Figure 1. 5 Graphical representation of mAb conjugated liposomes complexed with cDNA .....	29
Figure 2. 1 Graphical representation .....	46
Figure 3. 1 Working of NanoDrop instrument for the assessment of cDNA concentration .....	48
Figure 3. 2 Arrangement of agarose gel electrophoresis unit .....	50
Figure 3. 3 Spectra of ssDNA (p11 cDNA) using NanoDrop .....	52
Figure 3. 4 Detection of quantifiable range of p11 cDNA .....	54
Figure 3. 5 Calibration curve of p11 cDNA using gel electrophoresis ranging from 10 ng to 60 ng .....	55
Figure 3. 6 The correlation curve of cDNA concentrations in ng/ $\mu$ L and peak area .....	55
Figure 3. 7 Overlay spectra of TNBSA (TNBS) assay for DOPE.....	57
Figure 3. 8 The correlation spectra of TNBS assay for DOPE.....	57
Figure 3. 9 Calibration curve for Bradford assay .....	58
Figure 4 (A). 1 p11 plasmid vector map.....	67
Figure 4 (A). 2 eGFP plasmid vector map.....	68
Figure 4 (A). 3 Cultures for plasmid preparation .....	75
Figure 4 (A). 4 Plasmid digestion by restriction enzymes .....	80
Figure 4 (A). 5 Digestion of p11 cDNA .....	81
Figure 4 (B). 1 Reaction mechanism of amide formation between DOPE and Boc- Arg (Mtr)-OH .....	84
Figure 4 (B). 2 Reaction mechanism of amide formation between DOPE and N $\alpha$ ,N $\beta$ -di-Boc-L-lysine .....	86
Figure 4 (B). 3 Reaction mechanism of amide formation between DOPE and N im -di-Boc-L-Histidine .....	87
Figure 4 (B). 4 TNBS reaction scheme for the detection of primary amines present in DOPE .....	88
Figure 4 (B). 5 IR spectra of DOPE.....	91
Figure 4 (B). 6 IR spectra of Di-Boc-Arginine and arginine conjugated DOPE.....	92

Figure 4 (B). 7 IR spectra of Di-BOC-Lysine and lysine conjugated DOPE .....	93
Figure 4 (B). 8 IR spectra of Di-BOC-Histidine and histidine conjugated DOPE .....	94
Figure 4 (B). 9 Titration of DOPE and amino acid modified DOPE with 1 N HCl.....	96
Figure 4 (B). 10 UV spectra of TNBS assay for DOPE and amino acid modified DOPE.	97
Figure 4 (B). 11 Blank and standard chromatograms generated by GC.....	98
Figure 4 (B). 12 GC chromatograms of amino acid modified DOPE for detection of DCM .....	99
Figure 5. 1 Structures of HSPC, DPPE and Cholesterol .....	104
Figure 5. 2 Conversion of MTT to purple coloured Formazan dye.....	115
Figure 5. 3 Transwell arrangement for permeation study.....	117
Figure 5. 4 Normal plot of residuals for particle size .....	131
Figure 5. 5 Residuals vs. predicted response plot for particle size .....	131
Figure 5. 6 Residual vs. run order plot for particle size.....	132
Figure 5. 7 Predicted vs. actual plot for particle size.....	132
Figure 5. 8 Plots of residual vs individual factor to determine the time dependency of variable.....	134
Figure 5. 9 Box-cox plot for particle size .....	135
Figure 5. 10 Trace plot for particle size.....	136
Figure 5. 11 Two component mixture plots for particle size.....	137
Figure 5. 12 Contour and response surface plot for particle size .....	139
Figure 5. 13 Normal plot of residuals for PDI.....	142
Figure 5. 14 Residual vs predicted pot for PDI .....	142
Figure 5. 15 Residual vs. run order plots for PDI.....	143
Figure 5. 16 Predicted vs. actual plot for PDI .....	143
Figure 5. 17 Box-cox plot for PDI.....	144
Figure 5. 18 Trace plot for PDI.....	145
Figure 5. 19 Two component mixture plots for PDI.....	146
Figure 5. 20 Contour and response surface plot for PDI .....	148
Figure 5. 21 Desirability plot for optimised batch selection.....	150
Figure 5. 22 Design space with optimum response parameters.....	151
Figure 5. 23 Particle size distribution of liposomes for predicted batches formulated from modified lipids .....	153
Figure 5. 24 Cryo-TEM image for lipoplex.....	154

Figure 5. 25 Complexation efficiency of cationic liposomes formulated from modified lipids with p11 cDNA.....	156
Figure 5. 26 Effects of pH on complexation efficiency lipoplex.....	158
Figure 5. 27 Effect of temperature on complexation efficiency of lipoplex.....	159
Figure 5. 28 Effects of sodium sulphate concentration on liposome formulated from modified lipids .....	160
Figure 5. 29 Stability of lipoplex formulated from modified lipids in presence heparin .	161
Figure 5. 30 Serum stability studies lipoplex formulated from modified lipids.....	163
Figure 5. 31 Graph of haemolytic potential of lipoplex formulated from modified lipids.....	164
Figure 5. 32 Erythrocyte aggregation potential of lipoplex formulated from modified lipids.....	165
Figure 5. 33 % Cell viability at various L/P ratio for modified lipoplex formulations ....	166
Figure 5. 34 Cellular uptake of following formulations (A) DOPE-H, (B) DOPE-L, (C) DOPE-A, (D) naked DNA and (E) Lipofectamine-2000 .....	168
Figure 5. 35 Graph of cell permeation ability of lipoplex formulation through SHSY5Y cell line .....	169
Figure 5. 36 Western blot analysis of p11 protein in cells and correlated graph.....	170
Figure 5. 37 mRNA level in cells treated with interferon, naked DNA and modified liposomes .....	172
Figure 6. 1 Droplet size measurement instruments.....	181
Figure 6. 2 SDS mechanism of action .....	185
Figure 6. 3 Graphical representation of western blot procedure.....	200
Figure 6. 4 Effects of Actuation distance on Droplet size distribution and Span value ...	203
Figure 6. 5 Effects of Spraying angle on droplet size distribution and span value .....	204
Figure 6. 6 Effects of stroke length on droplet size distribution and span value.....	204
Figure 6. 7 Effects of actuation force on droplet size distribution and span value.....	205
Figure 6. 8 Droplet size distribution of optimised formulation .....	205
Figure 6. 9 Spray angle and spray pattern of optimised formulation .....	206
Figure 6. 10 Permeation of cDNA through sheep mucosa .....	208
Figure 6. 11 Histopathology of nasal mucosa after treatment with lipoplex.....	209
Figure 6. 12 Coomassie staining of IGF-II conjugated liposomal formulations .....	212
Figure 6. 13 Complexation efficiency of IGF-II targeted DOPE-A lipoplex.....	213
Figure 6. 14 Size of IGF-II targeted lipoplex .....	214

Figure 6. 15 Cytotoxicity of targeted and non-targeted lipoplex formulations .....	214
Figure 6. 16 Live imaging of SHSY5Y cells using confocal microscope after treatment with IGF-II targeted DOPE-A lipoplex .....	215
Figure 6. 17 Live imaging of SHSY5Y cells using confocal microscope after treatment with DOPE-A lipoplex.....	216
Figure 6. 18 Live imaging of SHSY5Y cells using confocal microscope after treatment naked cDNA .....	217
Figure 6. 19 Confocal images of cryo-sectioned nasal mucosa after intranasal treatment with naked DNA and lipoplex formulation .....	221
Figure 6. 20 Confocal images of cryo sectioned brain tissue after treatment with (A) i.v. naked DNA, (B) i.v non-targeted lipoplex, (C) i.v. targeted lipoplex, (D) intranasal delivery of naked DNA, (E) intranasal delivery of lipoplex.....	223
Figure 6. 21 Dose dependency of Interferon induced depression model.....	224
Figure 6. 22 Western blot analysis of p11 protein in animal brain tissue.....	225
Figure 6. 23 Gene expression in mice treated with PBS, Interferon and final formulations .....	226